Mepolizumab for Severe Asthma With Chronic Rhinosinusitis Mepolizumab for Severe Asthma With Chronic Rhinosinusitis
Mepolizumab may be an effective treatment option for patients with severe asthma and underlying eosinophilic chronic rhinosinusitis.BMC Pulmonary Medicine
Publication date: Available online 15 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Rory Chan, Chris RuiWen Kuo, Brian Lipworth
ConclusionsPooled data indicate that short- and long-term timothy grass SLIT-tablet is well tolerated in children, regardless of geographic region. AEs were generally local, mild, and transient allergic reactions.
We examined which patients respond to systematic assessment and whether oral corticosteroid burden can be decreased independent of monoclonal biologic use.MethodsSpecialist-referred patients are assessed systematically for difficult asthma at our centre. We undertook a responder analysis for improvements in the domains of symptom control, quality of life, exacerbations and airflow obstruction, assessed six months after initial assessment. Multivariate analyses were performed for each domain to identify predictors of response. Changes in oral corticosteroid burden were also measured, stratified by monoclonal biologics comme...
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Perla A. Vargas
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Luis Pérez de Llano, David Dacal Rivas
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): J. Andrew Bird, Stephanie Leonard, Marion Groetch, Amal Assa'ad, Antonella Cianferoni, April Clark, Maria Crain, Tracy Fausnight, David Fleischer, Todd Green, Matthew Greenhawt, Linda Herbert, Bruce J. Lanser, Irene Mikhail, Shahzad Mustafa, Sally Noone, Christopher Parrish, Pooja Varshney, Berber Vlieg-Boerstra, Michael C. YoungOral food challenges are an integral part of an allergist's practice and are used to evaluate the presence or absence of allergic reactivity to foods. A work group within t...
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Brian Lipworth, Rory Chan, Chris RuiWen Kuo
Oral food challenges (OFCs) are the gold standard in the diagnosis of food-related allergic symptoms and can help determine if a food can be safely reintroduced into the diet.1-3 Following a negative OFC, patients are recommended to regularly consume the food.1,4 While data are limited, there are multiple published cases of recurrence of peanut allergy after a negative OFC when there is infrequent consumption.1,4,5 In 2015 van der Valk et al. found that among a group of Dutch patients, successful reintroduction was as low as 56% due to a number of patients having reactions to the food even after a negative OFC.
Peanut allergy (PA) affects ∼1.6 million US children. The current standard of care is strict avoidance and prompt reaction treatment. PA healthcare costs and healthcare resource utilization (HCRU) are poorly understood.
AbstractPurpose of ReviewThe prevalence of food allergy is increasing. At the current time, there are no approved treatments for food allergy. Major limitations of immunotherapy are long treatment periods (months or years), frequent clinic visits, high costs, increased risk of adverse events during treatment, and lack of durability of desensitization. Additionally, it is allergen-specific, and in those allergic to multiple allergens, the length and cost of treatment are further increased. In this review, we summarize recent developments in novel non-allergen-specific treatments for food allergy.Recent FindingsA number of m...